Zefazone side effects, by duration, gender and age (a phase IV clinical study of FDA data)

Summary:

Side effects are reported by people who take Zefazone (cefmetazole sodium). Common side effects include angina pectoris among females and acute respiratory distress syndrome among males.

The phase IV clinical study is created by eHealthMe based on 27 reports from the FDA, and is updated regularly.

What is Zefazone?

Zefazone has active ingredients of cefmetazole sodium. eHealthMe is studying from 29 Zefazone users. Check the latest studies of Zefazone.



On Jul, 25, 2026

27 people who take Zefazone and have side effects are studied.

Zefazone side effects.

What are the common side effects of Zefazone, by gender? *:

female:

  1. Angina pectoris (chest pain due to ischemia of the heart muscle)
  2. Alanine aminotransferase increased

male:

  1. Acute respiratory distress syndrome
  2. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  3. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  4. Alanine aminotransferase increased
  5. Apgar score low
  6. Biopsy bone marrow abnormal
  7. Brain hypoxia (reduced supply of oxygen to the brain)
  8. Cerebral infarction (less blood supply to brain resulting tissue damage)
  9. Drug hypersensitivity
  10. Haematemesis (vomiting of blood)

What are the common side effects of Zefazone, by age (0-1 to 60+) *:

0-1:

  1. Alanine aminotransferase increased

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Alanine aminotransferase increased

50-59:

  1. Haematemesis (vomiting of blood)
  2. Disseminated intravascular coagulation (systemic activation of blood coagulation)

60+:

  1. Acute respiratory distress syndrome
  2. Angina pectoris (chest pain due to ischemia of the heart muscle)
  3. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  4. Biopsy bone marrow abnormal
  5. Brain hypoxia (reduced supply of oxygen to the brain)
  6. Cerebral infarction (less blood supply to brain resulting tissue damage)
  7. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  8. Drug hypersensitivity

What are the common side effects of Zefazone, by the time people have been on the drug (< 1 month to 10+ years)? *:

< 1 month:

n/a

1 - 6 months:

n/a

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:

  1. Acute respiratory distress syndrome
  2. Alanine aminotransferase increased
  3. Haematemesis (vomiting of blood)
  4. Angina pectoris (chest pain due to ischemia of the heart muscle)
  5. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  6. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  7. Apgar score low
  8. Biopsy bone marrow abnormal
  9. Brain hypoxia (reduced supply of oxygen to the brain)
  10. Cerebral infarction (less blood supply to brain resulting tissue damage)

* Approximation only. Some reports may have incomplete information.

Do you take Zefazone?

- Personalize this study to your gender and age
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.



How the study uses the data?

The study is based on cefmetazole sodium (the active ingredients of Zefazone) and Zefazone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.

Related studies are listed below in case you need more information:

Alternative drugs to, pros and cons of Zefazone:

All Zefazone side effects from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: